PMC

CONSORT diagram of study participants. EFT, early fast‐acting treatment; MG, myasthenia gravis.

(A) Kaplan–Meier curves for the first achievement of the treatment target (MM or better‐5mg for ≥6 months) in both the EFT and non‐EFT groups. (B) Baseline cumulative hazard curves for both the EFT and non‐EFT groups, excluding the effects of the covariables as a function of time. EFT, early fast‐acting treatment; MM, minimal manifestations.

(A) Kaplan–Meier curves for first achievement of the treatment target (MM or better‐5mg for ≥6 months) in both groups of the EFT with the low‐ and high‐dose PSL regimens. (B) Time courses of the baseline cumulative hazard curves for both the low‐dose and high‐dose PSL groups as a function of time. EFT, early fast‐acting treatment; MM, minimal manifestations; PSL, prednisolone.